Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME

KETOPROFEN

NFPA

PRODUCT USE

A phenylpropionic acid derivative which has analgesic, anti- inflammatory, and anti-
pyretic (reduces fever) properties. Used in the treatment of rheumatic arthritis and other
musculoskeletal disorders. Has also been used in the treatment of acute gout. Usually
administered by mouth. WARNING: This medication may be dangerous when used in large
amounts or for long time and is for the relief of minor and temporary ailments. Should be
used strictly as directed. Prolonged use without medical supervision could be dangerous.

SYNONYMS

C16-H14-O3, "propionic acid, 2-(3-benzoylphenyl)-", "propionic acid, 2-(3-
benzoylphenyl)-", "benzeneacetic acid, 3-benzoyl-alpha-methyl-", "benzeneacetic acid, 3-
benzoyl-alpha-methyl-", "m-benzoylhydratropic acid", "m-benzoylhydratropic acid", "3-
benzoylhydratropic acid", "3-benzoylhydratropic acid", "3-benzoyl-alpha-
methylbenzeneacetic acid", "3-benzoyl-alpha-methylbenzeneacetic acid", "2-(m-
benzoylphenyl)propionic acid", "2-(m-benzoylphenyl)propionic acid", "2-(3-
benzoylphenyl)propionic acid", "2-(3-benzoylphenyl)propionic acid", Alrheunum, Aneol,
Capisten, Epatec, Orudis, Oruvail, RP-19583, RU-4733, "phenylpropionic analgesic/
antipyretic/ anti-inflammatory"

Section 2 - HAZARDS IDENTIFICATION

CANADIAN WHMIS SYMBOLS

EMERGENCY OVERVIEW

RISK

Toxic if swallowed.

POTENTIAL HEALTH EFFECTS

ACUTE HEALTH EFFECTS

SWALLOWED

  Toxic effects may result from the accidental ingestion of the material; animal experiments indicate that ingestion of less than 40 gram may be fatal or may produce serious damage to the health of the individual.  

EYE

  Although the material is not thought to be an irritant, direct contact with the eye may produce transient discomfort characterized by tearing or conjunctival redness (as with windburn).  

SKIN

  The material is not thought to produce adverse health effects or skin irritation following contact (as classified using animal models). Nevertheless, good hygiene practice requires that exposure be kept to a minimum and that suitable gloves be used in an occupational setting.  Open cuts, abraded or irritated skin should not be exposed to this material.  Toxic effects may result from skin absorption.  

INHALED

  Inhalation may produce health damage*.  The material is not thought to produce respiratory irritation (as classified using animal models). Nevertheless inhalation of the material, especially for prolonged periods, may produce respiratory discomfort and occasionally, distress.  

CHRONIC HEALTH EFFECTS

  Principal routes of exposure are by accidental skin and eye contact andinhalation of generated dusts.  Mice and rats receiving 12 and 9 mg/kg body weight/day of ketoprofen  did not show evidence of teratogenicity or embryotoxicity.  Maternally toxic doses produced embryotoxic effects in rabbits but did  not produce a teratogenic response.  Abnormalities of liver-function tests, impairment of renal function,  agranulocytosis and thrombocytopenia may be longer term manifestations of  substance exposure. Haemolytic and aplastic anaemia, neutropenia and  decreases in haemoglobin and haematocrit have also occurred following use  of the congener, Ibuprofen.  Persons sensitive to any non-steroidal anti-inflammatory drugs may also be  sensitive to ketoprofen.  Chronic ingestion of excessive amounts of non-narcotic analgesics can lead to nephropathy (kidney damage) in humans. A substantial number of health deficits are associated with this condition. The include reduced GFR (glomerular filtration rate), salt wastage, hyperkalaemia, metabolic acidosis, and a vasopressin-resistant concentration defect. More severe forms of analgesic nephropathy may lead to papillary necrosis with sloughing of the papilla. Although renal function may return to normal after discontinuation of treatment or abuse, complete anuria (absence of urine formation) may result following continued abuse.  Most patients who develop analgesic nephropathy consume analgesics for up to 3 years, consuming between 2 and 5 mg daily.  Exposure to small quantities may induce hypersensitivity reactions characterized by acute bronchospasm, hives (urticaria), deep dermal wheals (angioneurotic edema), running nose (rhinitis) and blurred vision . Anaphylactic shock and skin rash (non-thrombocytopenic purpura) may occur. An individual may be predisposed to such anti-body mediated reaction if other chemical agents have caused prior sensitization (cross-sensitivity).